Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | CTACK | 32.0 | 53 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | CTACK | 28.0 | 55 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 1 | CTACK | 35.5 | 64 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | CTACK | 33.0 | 69 | |
N2759 | IL-1 alpha | 100 | ng/mL | 1 | CTACK | 28.5 | 56 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | CTACK | 31.0 | 55 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 1 | CTACK | 28.5 | 60 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | CTACK | 33.0 | 33 | |
N2586 | IL-1 alpha | 100 | ng/mL | 1 | CTACK | 30.0 | 38 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 16.5 | 40 | |
RA1869 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 15.0 | 59 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 16.0 | 52 | |
N2759 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 16.0 | 53 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 16.0 | 58 | |
RA1931 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 16.0 | 78 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 16.0 | 51 | |
N2586 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 17.5 | 60 | |
RA1869 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 15.0 | 58 | |
RA1869 | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 20.0 | 33 | ||||
N2759 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 18.0 | 66 | |
N2759 | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 15.0 | 63 | ||||
RA1931 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 16.0 | 71 | |
RA1931 | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 18.5 | 48 | ||||
N2586 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 16.0 | 36 | |
N2586 | Poly(I:C) | 2 | ug/mL | 1 | CTACK | 17.5 | 54 |